Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors
Shots:
- EirGenix to receive upfront- milestones with profit sharing on sales and will be responsible for the development & manufacturing of proposed biosimilar trastuzumab. Sandoz to get WW rights to commercialize the proposed biosimilar trastuzumab (Ex- China & Taiwan)
- The agreement is the third biosimilar collaboration for Sandoz in 18 months- which will further focus on the expansion of its oncology portfolio with four oncology biosimilars
- Proposed trastuzumab biosimilar is been evaluated in P-III study for HER2+ breast and gastric cancer tumors. Additionally- Sandoz has 8 approved biosimilars and 10+ in the development phase for oncology- supportive cancer care- and hematology
Ref: Sandoz | Image: Behance
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com